Find information on thousands of medical conditions and prescription drugs.

Teriparatide

Teriparatide (Forsteo®) is a recombinant form of parathyroid hormone, used in the treatment of advanced osteoporosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Administration

Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 ╬╝g per day.

Uses

Teriparatide is a third-line agent in osteoporosis, after calcium/vitamin D supplementation and bisphosphonates. The bisphosphonates are effective in a large majority of osteoporosis patients, and only a minority would normally require teriparatide.

Mechanism of action

Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.

FDA approval

Forsteo was approved by the FDA on 26 November 2002, for the treatment of osteoporosis in postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Read more at Wikipedia.org


[List your site here Free!]


Lilly's Teriparatide Gets Positive Opinion From European Cpmp
From Worldwide Biotech, 2/1/03

Lilly (NYSE:LLY) has announced that the European Committee for Proprietary Medicinal Products (CPMP) has issued a positive opinion for teriparatide (rDNA origin) injection (proposed European brand name FORSTEO(R)), a bone formation agent for the treatment of established osteoporosis in postmenopausal women who are at high risk of a fracture. The CPMP has recommended to the European Commission that approval for teriparatide should be granted. Teriparatide, which will be known in the rest of the world as FORTEO(R), has already received U.S. Food and Drug Administration (FDA) approval.

"We are extremely pleased by the CPMP's recommendation for approval of teriparatide in Europe," said John C. Lechleiter, Ph.D., Lilly executive vice president, pharmaceutical products and corporate development. "The adoption of a positive opinion for teriparatide by the CPMP underscores the strength of the scientific data supporting the use of this unique and innovative product to treat a devastating disease."

The CPMP, comprised of regulators from the European Union countries, based its positive opinion on its review of the comprehensive data package for teriparatide. More than 2,800 women and men were randomized in studies to characterize the safety and efficacy of teriparatide.

Following the CPMP's positive opinion, the application will be reviewed by the European Commission (EC), which has authority to grant marketing authorization for the European Union. Lilly anticipates a decision from the EC in Spring 2003.

"There is a great need for new treatment options for severe osteoporosis. Every 30 seconds someone in Europe has a fracture as a result of osteoporosis," said Richard Pilnik, president of European operations for Lilly. "If approved by the European Commission, teriparatide would be the first bone formation agent available for marketing in all of the EU, providing a new treatment approach for those with established osteoporosis who are at high risk of osteoporosis-related fracture."

A Critical Need

Osteoporosis is a global problem, affecting more than 150 million people worldwide. One in three postmenopausal women will be affected by osteoporosis(1), and as the population of the world both grows and ages it is becoming an increasingly significant cause of mortality and morbidity(2). Studies suggest that osteoporosis may be a quickly progressing disease once a fracture occurs. The accumulation of multiple spinal fractures may result in pain, height loss, deformity, functional limitations and diminished quality of life(3). The condition costs national treasuries in the EU more than EURO 4.8 billion annually in hospital healthcare alone.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information -- for some of the world's most urgent medical needs.

For more information, call 317/985-4045.

COPYRIGHT 2003 Worldwide Videotex
COPYRIGHT 2003 Gale Group

Return to Teriparatide
Home Contact Resources Exchange Links ebay